Medisyn Technologies

Infectious Disease

Infectious Disease

HIV/AIDS
Protease Inhibition

MRSA

Tuberculosis

Unmet Need - Infectious disease is a global health issue. Viral and bacterial infections around the world mutate and are becoming resistant to common treatments. The issue of resistance requires the development of new agents that incorporate mechanisms not only effective for treating the disease but also able to reduce or eliminate the development of drug resistance.

Our Approach - Medisyn has developed antibacterial and antiviral models using existing and experimental treatment data collected from public health databases. Coupled with additional models to address bacterial and viral replication, kill, and other anti-resistance methods, Medisyn is developing the next generation of infectious disease agents.

Pipeline Highlights:

HIV/AIDS
In response to a request from a collaborator, Medisyn has developed models to discover novel and potent protease inhibitors. Finding new protease inhibitors has been a challenge for the drug discovery industry because traditional methods that yield clues to activity based on structural relationships have not been successful. Using Medisyn's unique topological methods, we have found novel compounds and are continuing development.

MRSA
MRSA, or methicillin-resistant Staphylococcus aureus, is a strain of staph that's resistant to the broad-spectrum antibiotics commonly used to treat it. MRSA's appearance is becoming more frequent in hospital's and infections have been reported in broader communities. Because of its resistant nature, the inability to treat it can be fatal. It is one of the most serious public health concerns today. Finding new antibacterial agents is necessary to address the risk of developing antibacterial resistance. Medisyn is developing models to discover novel, specific and potent compounds for MRSA and is currently testing candidates for development.

Tuberculosis
Tuberculosis, or TB, is another bacterial infection that requires long terms antibacterial agent administration. To reduce the risk of developing resistance, new agents need to be identified. Medisyn has developed models using extensive experimental research and is currently testing candidates for development.